Research Article
Imiquimod 3.75% Cream Applied Daily to Treat Anogenital Warts: Combined Results from Women in Two Randomized, Placebo-Controlled Studies
Table 4
Summary of local skin reactions, maximum intensity during evaluation period.
| | Placebo | Imiquimod 2.5% | Imiquimod 3.75% | Women | 105a | 193a | 203a |
| Local skin reaction (LSR), (%) | | | | Any LSR grade other than none | 35 (33.3) | 135 (69.9) | 156 (76.8) | Severe grade | | | | Any | 1 (1.0) | 26 (13.5) | 36 (17.7) | Erythema | 0 (0) | 18 (9.3) | 20 (9.9) | Edema | 0 (0) | 5 (2.6) | 4 (2.0) | Weeping/exudates | 0 (0) | 1 (0.5) | 2 (1.0) | Flaking/scaling/dryness | 0 (0) | 2 (1.0) | 0 (0) | Scabbing/crusting | 0 (0) | 0 (0) | 1 (0.5) | Erosion/ulceration | 1 (1.0) | 17 (8.8) | 26 (12.8) |
|
|
aDenominator is the number of women with at least 1 postbaseline assessment.
|